First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free beta-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome

摘要

The first trimester screening programme offers a noninvasive option for the early detection of aneuploidy pregnancies. This screening is done by a combination of two biochemical markers i.e. serum free /?-human chorionic gonadotrophin (free /?-hCG) and pregnancy associated plasma protein A (PAPP-A), maternal age and fetal nuchal translucency (NT) thickness at 11 +0-13+6 weeks of gestation. A beneficial consequence of screening is the early diagnosis or trisomies 21, 18 and 13. At 11 + 0-13 + 6 weeks, the relative prevalence of trisomies 18 and 13 to trisomy 21 are found to be one to three and one to seven, respectively. All three trisomies are associated with increased maternal age, increased fetal NT and decreased PAPP-A, but in trisomy 21 serum free beta-hCG is increased whereas in trisomies 18 and 13 free beta-hCG is decreased.